Table 4.

Summary of the main results data from the SOCRATES-PRESERVED and VITALITY trials.

Trial	Inclusion Criteria	Patients	Treatment	Results
SOCRATES-PRESERVED [30]	HFpEF (LVEF ≥ 45%), <4 weeks from HF decompensation NYHA II-IV, BNP ≥ 100 ng/L or NT-proBNP ≥ 300 ng/L (BNP ≥ 200 ng/L or NT-proBNP ≥ 600 ng/L if AF), Left atrial enlargement.	477 (325 patients completed treatment)	Vericiguat fixed-dose treatment arms (1.25 mg or 2.5 mg) and vericiguat up-titrated treatment arms (2.5–5 mg, 2.5–10 mg daily) vs. placebo	Primary endpoint: no significant difference change in NT-proBNP levels (p = 0.20) and change in LAV (p = 0.37) from baseline vs. placebo to 12 weeks. Exploratory endpoint: improve KCCQ score change from baseline (mean difference: 19.8 points) vs. placebo (mean difference: 9.2 points) to 12 weeks.
VITALITY [31]	HFpEF (LVEF ≥ 45%), NYHA II-III, HFH or HF requiring iv diuretics < 6 months, BNP ≥ 100 ng/L or NT-proBNP ≥ 300 ng/L (BNP ≥ 200 ng/L or NT-proBNP ≥ 600 ng/L if AF), Left ventricular hypertrophy or left atrial enlargement.	789 (761 included in primary analysis)	Vericiguat (up-titrated to 15 mg or 10 mg) vs. placebo	Primary endpoint: no significant change in KCCQ to 24 weeks. Secondary outcome: no difference in 6MWT to 24 weeks.

6MWT = six-minute walk test; AF = atrial fibrillation; BNP = B-type natriuretic peptide; HFH = heart failure hospitalization; HFpEF = heart failure with preserved ejection fraction; KCCQ = Kansas City Cardiomyopathy Questionnaire; LAV = left atrial volume; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association.